According to GlobalData’s medical device pipeline database, 83 Topical Absorbable Hemostats devices are in various stages of development globally. GlobalData’s report Topical Absorbable Hemostats provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 26 are in active development, while the remaining 57 are in an inactive stage of development. There are 12 products in the early stages of development, and the remaining 14 are in the late stages of development.
Topical absorbable hemostats are agents used to promote and accelerate hemostasis to control bleeding in cases where application of pressure, ligature and other conventional methods is ineffective. They are inserted to remove excess blood, thereby preventing further bleeding and clearing up the operating site for the surgeon. TAH products are often plant or gelatin based and act as mechanical barriers and/or help with vasocontriction and a platform for platelet aggregation in order to slow the flow of blood and give the patient’s body time to form a clot. Flowable hemostats or fibrin sealants are not covered in this model, as those products are tracked under the Tissue Sealants and Adhesives model. Hemostats include active hemostats (thrombin based hemostats), and combination and passive hemostats (oxidized regenerated cellulose based hemostats, gelatin based hemostats, polysaccharide based hemostats collagen based hemostats).
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Topical Absorbable Hemostats pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Topical Absorbable Hemostats devices. Overall, most of these Topical Absorbable Hemostats pipeline devices are being developed by private entities.
Key players involved in the active development of Topical Absorbable Hemostats include United Health Products, Xcede Technologies, Arch Therapeutics, Biomedica Management, CR Bard, Hemostasis, Medcura, Miraqules Medsolutions, GATT Technologies and Haemostatix.
For a complete picture of the developmental pipeline for Topical Absorbable Hemostats devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
